目的:探讨熊去氧胆酸联合双歧杆菌四联活菌片治疗对高胆红素血症新生儿各心肌酶谱指标、免疫功能因子及炎症因子水平的影响。方法:选取我院收治的高胆红素血症新生儿100例,随机分为对照组与观察组,每组50例。两组均给予常规对症治疗。对照组给予熊去氧胆酸治疗；观察组在对照组治疗基础上,给予双歧杆菌四联活菌片治疗,均治疗7 d。检测两组患儿治疗前及治疗7 d后,血清中CK-MB、CK、LDH、AST、CD3+、CD4+、CD4+/CD8+、CD8＋、CRP及TNF-α水平。结果:治疗前,两组血清中CK-MB、CK、LDH、AST、CD3+、CD4+、CD4+/CD8+、CD8＋、CRP及TNF-α水平相当(P＞0.05)。治疗后,两组血清中CK-MB、CK、LDH、AST、CD8＋、CRP、TNF-α水平较本组治疗前均明显降低,CD3+、CD4+、CD4+/CD8+水平均明显升高,且治疗后观察组血清中CK-MB、CK、LDH、AST、CD8＋、CRP、TNF-α水平均明显低于对照组,CD3+、CD4+、CD4+/CD8+水平均明显高于对照组(P＜0.05)。结论:熊去氧胆酸联合双歧杆菌四联活菌片可以通过降低高胆红素血症新生儿各心肌酶谱指标活性,改善炎症状态,增强患儿免疫功能,提高临床疗效。
Objective: To investigate the effects of myocardial enzyme, immune function and inflammatory response by ursodeoxycholic acid combined with bifidobacterium quadruple preparations on hyperbilirubinemia neonatal. Methods:100 cases of neonatal hyperbilirubinemia in our hospital from June 2016 to May ~2017 were selected and divided into control group and observation group by random number table, 50 cases in each group. Two groups of neonatal were given routine symptomatic treatment. The control group was treated with ursodeoxycholic acid and the observation group was treated with Bifidobacterium tetralogy of live bacteria on the basis of the control group. The two groups of neonatal were both treated for 7 days。The serum levels of CK-MB, CK, LDH, AST, CD3+, CD4+, CD4+/CD8+, CD8 +, CRP and TNF-α were measured before and after the treatment of the two groups. Results:Before treatment, there was no significant difference in serum CK-MB, CK, LDH, AST, CD3+, CD4+, CD4+/CD8+, CD8 +, CRP and TNF-α levels between the 2 groups (P>0.05). After treatment:2 groups of serum CK-MB, CK, LDH, AST, CD8 +, CRP, TNF-α levels significantly decreased compared with the group before treatment, CD3+, CD4+ and CD4+/CD8+ levels were significantly increased after treatment, and the observation group with serum CK-MB, CK, LDH, AST, CD8 +, CRP, TNF-α levels were significantly lower than the control group, CD3+ CD4+ and CD4+/CD8+ levels were significantly higher than the control group, the differences were statistically significant (P<0.05). Conclusion: Ursodeoxycholic acid combined with Bifidobacterium quadruple viable tablets can can reduce the activity of myocardial enzyme spectrum index of neonatal hyperbilirubinemia, improve the state of inflammation, enhance the immune function of the neonatal hyperbilirubinemia and improve the clinical effect.